Skip to content
10-Q

Quarterly Report

PROPANC BIOPHARMA, INC. PPCB

0001493152-25-006697

← back to feed
Filed
Feb 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Feb 12, 2025 15.37K sh
Long Term Debt Q2 2025 · Dec 31, 2024 $409.8K
Long Term Debt Q2 2025 · Jun 30, 2024 $399.33K
Current Liabilities Q2 2025 · Dec 31, 2024 $4.15M
Current Liabilities Q2 2025 · Jun 30, 2024 $3.79M
Total Liabilities Q2 2025 · Dec 31, 2024 $4.24M
Total Liabilities Q2 2025 · Jun 30, 2024 $3.85M
Current Assets Q2 2025 · Dec 31, 2024 $17.98K
Current Assets Q2 2025 · Jun 30, 2024 $25.44K
Total Assets Q2 2025 · Dec 31, 2024 $78.53K
Total Assets Q2 2025 · Jun 30, 2024 $72.37K
Shares Diluted restated Q2 2025 · Dec 31, 2023 397 sh
Shares Diluted restated Q2 2025 · Dec 31, 2023 290 sh
Operating Cash Flow Q2 2025 · Dec 31, 2023 −$572.34K
Stockholders Equity Q2 2025 · Dec 31, 2023 −$3.56M
Stockholders Equity Q2 2025 · Sep 30, 2023 −$2.99M
Stockholders Equity Q2 2025 · Jun 30, 2023 −$3.12M
Eps Diluted restated Q2 2025 · Dec 31, 2023 −$1,559.55
Eps Diluted restated Q2 2025 · Dec 31, 2023 −$3,835.55
Eps Basic restated Q2 2025 · Dec 31, 2023 −$1,559.55
Eps Basic restated Q2 2025 · Dec 31, 2023 −$3,835.55
Sga Expense Q2 2025 · Dec 31, 2023 $318.19K
Sga Expense Q2 2025 · Dec 31, 2023 $712.01K
Rd Expense Q2 2025 · Dec 31, 2023 $114.02K
Rd Expense Q2 2025 · Dec 31, 2023 $130.26K
Net Income Q2 2025 · Dec 31, 2023 −$584.38K
Net Income Q2 2025 · Dec 31, 2023 −$935.25K
Net Income Q2 2025 · Sep 30, 2023 −$350.87K
Operating Income Q2 2025 · Dec 31, 2023 −$438.06K
Operating Income Q2 2025 · Dec 31, 2023 −$855.28K